Table 2.

Univariate and multivariate Cox proportional hazards regression models for OS: all patients (n = 1031)

Characteristic	Univariate analysis			Multivariate analysisa
	HR	95% CI	p value	HR	95% CI	P value
Age (ABC diagnosis) (≥ 60 years vs. < 60)	1.59	1.36–1.85	< 0.001	1.35	1.15–1.58	< 0.001
Treatment line of fulvestrant (4th or more vs. 3rd vs. 1st and 2nd)	0.68	0.61–0.75	< 0.001	1.00	0.90–1.12	0.965
ABC diagnosis to fulvestrant use (≥ 3 years vs. < 3)	0.16	0.13–0.19	< 0.001	0.14	0.12–0.18	< 0.001
Prior palliative chemotherapy (yes vs. no)	0.78	0.67–0.90	0.001	1.44	1.21–1.71	< 0.001
Histological or nuclear grade
(2 vs. 1)	1.74	1.45–2.08	< 0.001
(3 vs. 1)	2.30	1.86–2.85	< 0.001
Visceral metastasis (yes vs. no)	0.97	0.83–1.13	0.685
PgR (positive vs. negative)	1.17	0.98–1.39	0.089	1.29	1.06–1.59	0.013
HER2 (positive vs. negative)	0.84	0.65–1.09	0.200

OS overall survival, HR hazard ratio, CI confidence interval, ABC advanced breast cancer, PgR progesterone receptor HER2, human epidermal growth factor receptor 2

^an = 1030 in the multivariate analysis (one patient was excluded because date of recurrence was unknown. Histological/nuclear grade data were not included in this analysis because one-third of the data were missing